SYMBICORT RAPIHALER 80mcg / 4.5mcg per actuation Inhalation Aerosol 120 doses
RXDRUG-DR-XY45700
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Asthma: Budesonide/Formoterol (SYMBICORT RAPIHALER) is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate.
COPD: Budesonide/Formoterol (SYMBICORT RAPIHALER) is indicated in the regular treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD), with frequent symptoms and a history of exacerbations.
COPD: Budesonide/Formoterol (SYMBICORT RAPIHALER) is indicated in the regular treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD), with frequent symptoms and a history of exacerbations.
Dosage/Direction for Use
The dosage of Budesonide/Formoterol (SYMBICORT RAPIHALER) should be individualised according to disease severity.
When control has been achieved, the dose should be titrated to the lowest dose at which effective control of symptoms is maintained.
Budesonide/Formoterol (SYMBICORT RAPIHALER) maintenance therapy: Budesonide/Formoterol (Symbicort) taken as regular maintenance treatment, with a separate rapid-acting bronchodilator as rescue. Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times. (See Table 1.)
When control has been achieved, the dose should be titrated to the lowest dose at which effective control of symptoms is maintained.
Budesonide/Formoterol (SYMBICORT RAPIHALER) maintenance therapy: Budesonide/Formoterol (Symbicort) taken as regular maintenance treatment, with a separate rapid-acting bronchodilator as rescue. Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times. (See Table 1.)
Increasing use of a separate rapid acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy. (See Table 2.)
General information: The patients should be instructed that Budesonide/Formoterol (SYMBICORT RAPIHALER) must be used even when asymptomatic for optimal benefit.
There are no special dosing requirements for elderly patients.
There are no data available for use of Budesonide/Formoterol (SYMBICORT) in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver diseases.
Instructions for correct use of Budesonide/Formoterol (SYMBICORT RAPIHALER): On actuation of Budesonide/Formoterol (SYMBICORT RAPIHALER), a volume of the suspension is expelled from the canister at high velocity. When the patient inhales through the mouthpiece at the same time as actuating the inhaler, the substance will follow the inspired air into the airways.
Note: It is important to instruct the patient to: Carefully read the instructions for use, handling and disposal under Cautions for Usage.
Shake the inhaler gently prior to each use to mix its contents properly.
Prime the inhaler by actuating it twice into the air when the inhaler is new, has not been used for more than one week or if it has been dropped.
Place the mouthpiece in the mouth. While breathing in slowly and deeply, press the device firmly to release the medication. Continue to breathe in and hold the breath for approximately 10 seconds or as long as is comfortable.
Shake the inhaler again and repeat.
Rinse the mouth with water after inhaling the maintenance dose to minimise the risk of oropharyngeal thrush.
Clean the mouthpiece of the inhaler regularly, at least once a week with a clean dry cloth.
Do not put the inhaler into water.
There are no special dosing requirements for elderly patients.
There are no data available for use of Budesonide/Formoterol (SYMBICORT) in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver diseases.
Instructions for correct use of Budesonide/Formoterol (SYMBICORT RAPIHALER): On actuation of Budesonide/Formoterol (SYMBICORT RAPIHALER), a volume of the suspension is expelled from the canister at high velocity. When the patient inhales through the mouthpiece at the same time as actuating the inhaler, the substance will follow the inspired air into the airways.
Note: It is important to instruct the patient to: Carefully read the instructions for use, handling and disposal under Cautions for Usage.
Shake the inhaler gently prior to each use to mix its contents properly.
Prime the inhaler by actuating it twice into the air when the inhaler is new, has not been used for more than one week or if it has been dropped.
Place the mouthpiece in the mouth. While breathing in slowly and deeply, press the device firmly to release the medication. Continue to breathe in and hold the breath for approximately 10 seconds or as long as is comfortable.
Shake the inhaler again and repeat.
Rinse the mouth with water after inhaling the maintenance dose to minimise the risk of oropharyngeal thrush.
Clean the mouthpiece of the inhaler regularly, at least once a week with a clean dry cloth.
Do not put the inhaler into water.
Overdosage
An overdose of formoterol would likely lead to an exaggeration of effects that are typical for beta2-adrenergic agonists: tremor, headache, palpitations, and tachycardia. Hypotension, metabolic acidosis, hypokalaemia and hyperglycemia may also occur. Supportive and symptomatic treatment may be indicated. A dose of 90 micrograms administered during three hours in patients with acute bronchial obstruction and when given three times daily as a total of 54 micrograms/day for 3 days to stable asthmatics raised no safety concerns.
Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects may appear.
Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects may appear.
Contraindications
Hypersensitivity (allergy) to budesonide, formoterol or any of the excipients.
Special Precautions
It is recommended that the dose be tapered when long-term treatment is discontinued and should not be stopped abruptly.
If patient finds the treatment ineffective, or exceed the prescribed dose of Budesonide/Formoterol (SYMBICORT RAPIHALER), medical attention must be sought. Sudden and progressive deterioration in control of asthma or COPD is potentially life threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, eg, a course of oral corticosteroids, or antibiotic treatment if an infection is present.
Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.
Treatment with Budesonide/Formoterol (SYMBICORT RAPIHALER) should not be used to treat a severe exacerbation.
Physicians should closely follow the growth of children and adolescents taking long-term corticosteroids by any route, and weigh the benefits of the corticosteroid therapy against the possible risk of growth suppression (see Pharmacology: Toxicology: Preclinical Safety data under Actions).
Particular care is needed in patients transferring from oral steroids, since they may remain at risk of impaired adrenal function for a considerable time. Patients, who have required high-dose emergency corticosteroid therapy or prolonged treatment at the highest recommended dose of inhaled corticosteroids, may also be at risk. These patients may exhibit signs and symptoms of adrenal insufficiency when exposed to severe stress. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Budesonide/Formoterol (SYMBICORT RAPIHALER) should be administered with caution in patients with severe cardiovascular disorders (including heart rhythm abnormalities), diabetes mellitus, untreated hypokalaemia or thyrotoxicosis.
High doses of beta2-agonists can lower S-potassium by inducing a redistribution of potassium from the extracellular to the intracellular compartment, via stimulation of Na+/K+-ATPase in muscle cells. The clinical importance of this effect is uncertain.
Clinical studies and meta-analyses indicate that treatment of COPD with inhaled corticosteroids may lead to an increased risk of pneumonia. However, the absolute risk for budesonide is small. A meta-analysis of 11 COPD double blind trials including 10,570 patients did not demonstrate a statistically significant increased risk of pneumonia in patients treated with budesonide (with or without formoterol) compared to non-budesonide containing treatments (placebo or formoterol). The incidence rate of pneumonia reported as a serious adverse event was 1.9% per year on budesonide containing treatments and 1.5% per year on non-budesonide containing treatments. The pooled hazard ratio comparing all budesonide-containing versus non-budesonide containing treatments was 1.15 (95% CI: 0.83, 1.57). The pooled hazard ratio comparing budesonide/formoterol versus formoterol or placebo was 1.00 (95% CI: 0.69, 1.44). A causal relationship with budesonide-containing products has not been established.
Effects on ability to drive and use machines: Budesonide/Formoterol (SYMBICORT RAPIHALER) is not expected to adversely affect the ability to drive or use machines.
If patient finds the treatment ineffective, or exceed the prescribed dose of Budesonide/Formoterol (SYMBICORT RAPIHALER), medical attention must be sought. Sudden and progressive deterioration in control of asthma or COPD is potentially life threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, eg, a course of oral corticosteroids, or antibiotic treatment if an infection is present.
Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.
Treatment with Budesonide/Formoterol (SYMBICORT RAPIHALER) should not be used to treat a severe exacerbation.
Physicians should closely follow the growth of children and adolescents taking long-term corticosteroids by any route, and weigh the benefits of the corticosteroid therapy against the possible risk of growth suppression (see Pharmacology: Toxicology: Preclinical Safety data under Actions).
Particular care is needed in patients transferring from oral steroids, since they may remain at risk of impaired adrenal function for a considerable time. Patients, who have required high-dose emergency corticosteroid therapy or prolonged treatment at the highest recommended dose of inhaled corticosteroids, may also be at risk. These patients may exhibit signs and symptoms of adrenal insufficiency when exposed to severe stress. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Budesonide/Formoterol (SYMBICORT RAPIHALER) should be administered with caution in patients with severe cardiovascular disorders (including heart rhythm abnormalities), diabetes mellitus, untreated hypokalaemia or thyrotoxicosis.
High doses of beta2-agonists can lower S-potassium by inducing a redistribution of potassium from the extracellular to the intracellular compartment, via stimulation of Na+/K+-ATPase in muscle cells. The clinical importance of this effect is uncertain.
Clinical studies and meta-analyses indicate that treatment of COPD with inhaled corticosteroids may lead to an increased risk of pneumonia. However, the absolute risk for budesonide is small. A meta-analysis of 11 COPD double blind trials including 10,570 patients did not demonstrate a statistically significant increased risk of pneumonia in patients treated with budesonide (with or without formoterol) compared to non-budesonide containing treatments (placebo or formoterol). The incidence rate of pneumonia reported as a serious adverse event was 1.9% per year on budesonide containing treatments and 1.5% per year on non-budesonide containing treatments. The pooled hazard ratio comparing all budesonide-containing versus non-budesonide containing treatments was 1.15 (95% CI: 0.83, 1.57). The pooled hazard ratio comparing budesonide/formoterol versus formoterol or placebo was 1.00 (95% CI: 0.69, 1.44). A causal relationship with budesonide-containing products has not been established.
Effects on ability to drive and use machines: Budesonide/Formoterol (SYMBICORT RAPIHALER) is not expected to adversely affect the ability to drive or use machines.
Use In Pregnancy & Lactation
For Budesonide/Formoterol (SYMBICORT RAPIHALER) or the concomitant treatment with budesonide and formoterol no clinical data on exposed pregnancies are available. Data from an embryo-fetal development study in the rat, using the Budesonide/Formoterol (SYMBICORT RAPIHALER) formulation, showed no evidence of any additional effect from the combination or evidence of any effects attributable to the excipients on the rodent.
There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse effects in reproduction studies at very high systemic exposure levels (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).
Data on approximately 2500 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations. This is not likely to be relevant for humans given recommended doses.
During pregnancy, Budesonide/Formoterol (SYMBICORT RAPIHALER) should only be used when the benefits outweigh the potential risk, especially during the first 3 months and shortly before delivery. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.
A clinical pharmacology study has shown that inhaled budesonide Turbuhaler is excreted in breast milk. However, budesonide was not detected in nursing infant blood samples. Based on pharmacokinetic parameters, the plasma concentration in the child is estimated to be less than 0.17% of the mother's plasma concentration. Consequently, no effects due to budesonide are anticipated in breast-fed children whose mothers are receiving therapeutic doses of Budesonide/Formoterol (SYMBICORT). It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of Budesonide/Formoterol (SYMBICORT) to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse effects in reproduction studies at very high systemic exposure levels (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).
Data on approximately 2500 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations. This is not likely to be relevant for humans given recommended doses.
During pregnancy, Budesonide/Formoterol (SYMBICORT RAPIHALER) should only be used when the benefits outweigh the potential risk, especially during the first 3 months and shortly before delivery. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.
A clinical pharmacology study has shown that inhaled budesonide Turbuhaler is excreted in breast milk. However, budesonide was not detected in nursing infant blood samples. Based on pharmacokinetic parameters, the plasma concentration in the child is estimated to be less than 0.17% of the mother's plasma concentration. Consequently, no effects due to budesonide are anticipated in breast-fed children whose mothers are receiving therapeutic doses of Budesonide/Formoterol (SYMBICORT). It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of Budesonide/Formoterol (SYMBICORT) to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Adverse Reactions
Since Budesonide/Formoterol (SYMBICORT RAPIHALER) contains both budesonide and formoterol, the same type and intensity of undesirable effects as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug related adverse reactions are pharmacologically predictable side effects of beta2-agonist therapy, such as tremor and palpitations. These tend to be mild and disappear within a few days of treatment.
Adverse reactions, which have been associated with budesonide or formoterol, are given as follows: (See Table 3.)
Adverse reactions, which have been associated with budesonide or formoterol, are given as follows: (See Table 3.)
As with other inhalation therapy, paradoxical bronchospasm may occur in very rare cases.
Systemic efforts of inhaled corticosteroids may occur particularly at high doses prescribed for prolonged periods.
Treatment with beta2-agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
Systemic efforts of inhaled corticosteroids may occur particularly at high doses prescribed for prolonged periods.
Treatment with beta2-agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
Drug Interactions
Pharmacokinetic interactions: The metabolism of budesonide is primarily mediated by CYP3A4. Inhibitors of this enzyme, e.g. ketoconazole, itraconazole and ritonavir may therefore increase systemic exposure to budesonide. This is of limited clinical importance for short-term (1-2 weeks) treatment with potent CYP3A4 inhibitors, but should be taken into consideration during long-term treatment with potent CYP3A4 inhibitors.
Pharmacodynamic interactions: Beta-adrenergic blockers (including eye drops) can weaken or inhibit the effect of formoterol.
Budesonide and formoterol have not been observed to interact with any other drug used in the treatment of asthma.
Pharmacodynamic interactions: Beta-adrenergic blockers (including eye drops) can weaken or inhibit the effect of formoterol.
Budesonide and formoterol have not been observed to interact with any other drug used in the treatment of asthma.
Caution For Usage
Instructions for use, handling and disposal: Please read carefully before start taking/using this medicine: This leaflet contains information about Budesonide/Formoterol (SYMBICORT RAPIHALER) and how to use and clean the device. Please read the leaflet carefully before using the inhaler and refer to it when using the medicine. Clean the inhaler regularly (at least weekly). Follow the cleaning instructions at the end of the leaflet.
This medicine has been prescribed personally and should not pass it on to others. It may harm them, even if their symptoms are the same.
For further questions, ask your doctor, nurse or pharmacist.
The doctor, nurse or pharmacist will instruct the correct use of the inhaler.
Inhaler: The inhaler will already be assembled upon receiving it. Do not take the inhaler apart. If it becomes loose, then place it back and continue to use it as instructed.
Preparing the Inhaler for Use: Take the inhaler out of the moisture-protective foil before using it for the first time and throw away the foil. If the inhaler is new, if it has not been used for a week or more, or it has been dropped, shake it gently and release 2 puffs or actuations (for the 80/4.5 and 160/4.5 micrograms/actuation strengths) in the air to prepare it for use.
Taking the medicine: 1. Shake the inhaler gently before each use.
2. Remove the mouthpiece cover.
3. Hold the inhaler upright in front of mouth, using the thumb(s) at the base of the inhaler and index finger(s) on the top. Breathe out as far as the patient can and put the mouthpiece gently in the mouth, between the teeth, and close lips around it.
4. Start to breathe in deeply, comfortably and slowly through the mouth, press firmly down on the inhaler to release a puff of medicine.
5. Continue to breathe in and hold breath for approximately 10 seconds or as long as it is comfortable, take the inhaler from the mouth and the finger from the top of the inhaler.
6. Take another puff, as directed by the doctor, shake the inhaler gently then repeat steps 3 to 5.
7. Put the mouthpiece cover back to keep dust and other debris from getting into the medicine.
8. Rinse the mouth with water to remove any excess medicine.
Important Information: Cleaning Instructions: The mouthpiece of the inhaler will need to be cleaned regularly, at least once a week: Remove the mouthpiece cover.
Wipe the inside and outside of the mouthpiece opening with a clean, dry cloth.
Replace the mouthpiece cover.
Do not put the inhaler in water.
Do not try to take the inhaler apart.
Reading the Counter: The arrow on the counter on the top of the inhaler points to the number of inhalations (puffs) remaining in the inhaler.
The counter will count down toward zero ("0") each time it release a puff of medicine (either when preparing the inhaler for use or when taking the medicine).
When the arrow on the counter enters the yellow area, this means that there are about 20 puffs left.
It is very important to take note the number of inhalations (puffs) remaining in the inhaler by reading the counter. Discard the inhaler after the counter reaches zero ("0"), indicating the used the number of inhalations on the product label and box. The inhaler may not feel empty and it may continue to operate, but it will not get the right amount of medicine if the patient keep using it.
See also Dosage & Administration. The canister should not be broken, punctured or burnt, even when apparently empty.
The canister contains a pressurised liquid. Do not expose to temperatures above 50°C.
Instructions for the correct use of Budesonide/Formoterol (SYMBICORT RAPIHALER) with a spacer device: The use of Budesonide/Formoterol (SYMBICORT RAPIHALER) with a spacer device is recommended to enable patients with difficulty in co-ordinating inhalation with actuation, such as young children or the elderly, to derive greater therapeutic benefit.
Note: It is important to instruct the patient to: Carefully read the instructions for use.
On actuation of the aerosol, the dose is released into the inhalation chamber. The inhalation chamber is then emptied by two slow deep breaths. Young children may need to breathe 5-10 times through the mouthpiece. For further actuations, the procedure is repeated. For young children who are unable to breathe through the mouthpiece, a face mask can be used. Compatible face masks are available separately and care should be taken to ensure a good fit is achieved.
Incompatibilities: Not applicable.
This medicine has been prescribed personally and should not pass it on to others. It may harm them, even if their symptoms are the same.
For further questions, ask your doctor, nurse or pharmacist.
The doctor, nurse or pharmacist will instruct the correct use of the inhaler.
Inhaler: The inhaler will already be assembled upon receiving it. Do not take the inhaler apart. If it becomes loose, then place it back and continue to use it as instructed.
Preparing the Inhaler for Use: Take the inhaler out of the moisture-protective foil before using it for the first time and throw away the foil. If the inhaler is new, if it has not been used for a week or more, or it has been dropped, shake it gently and release 2 puffs or actuations (for the 80/4.5 and 160/4.5 micrograms/actuation strengths) in the air to prepare it for use.
Taking the medicine: 1. Shake the inhaler gently before each use.
2. Remove the mouthpiece cover.
3. Hold the inhaler upright in front of mouth, using the thumb(s) at the base of the inhaler and index finger(s) on the top. Breathe out as far as the patient can and put the mouthpiece gently in the mouth, between the teeth, and close lips around it.
4. Start to breathe in deeply, comfortably and slowly through the mouth, press firmly down on the inhaler to release a puff of medicine.
5. Continue to breathe in and hold breath for approximately 10 seconds or as long as it is comfortable, take the inhaler from the mouth and the finger from the top of the inhaler.
6. Take another puff, as directed by the doctor, shake the inhaler gently then repeat steps 3 to 5.
7. Put the mouthpiece cover back to keep dust and other debris from getting into the medicine.
8. Rinse the mouth with water to remove any excess medicine.
Important Information: Cleaning Instructions: The mouthpiece of the inhaler will need to be cleaned regularly, at least once a week: Remove the mouthpiece cover.
Wipe the inside and outside of the mouthpiece opening with a clean, dry cloth.
Replace the mouthpiece cover.
Do not put the inhaler in water.
Do not try to take the inhaler apart.
Reading the Counter: The arrow on the counter on the top of the inhaler points to the number of inhalations (puffs) remaining in the inhaler.
The counter will count down toward zero ("0") each time it release a puff of medicine (either when preparing the inhaler for use or when taking the medicine).
When the arrow on the counter enters the yellow area, this means that there are about 20 puffs left.
It is very important to take note the number of inhalations (puffs) remaining in the inhaler by reading the counter. Discard the inhaler after the counter reaches zero ("0"), indicating the used the number of inhalations on the product label and box. The inhaler may not feel empty and it may continue to operate, but it will not get the right amount of medicine if the patient keep using it.
See also Dosage & Administration. The canister should not be broken, punctured or burnt, even when apparently empty.
The canister contains a pressurised liquid. Do not expose to temperatures above 50°C.
Instructions for the correct use of Budesonide/Formoterol (SYMBICORT RAPIHALER) with a spacer device: The use of Budesonide/Formoterol (SYMBICORT RAPIHALER) with a spacer device is recommended to enable patients with difficulty in co-ordinating inhalation with actuation, such as young children or the elderly, to derive greater therapeutic benefit.
Note: It is important to instruct the patient to: Carefully read the instructions for use.
On actuation of the aerosol, the dose is released into the inhalation chamber. The inhalation chamber is then emptied by two slow deep breaths. Young children may need to breathe 5-10 times through the mouthpiece. For further actuations, the procedure is repeated. For young children who are unable to breathe through the mouthpiece, a face mask can be used. Compatible face masks are available separately and care should be taken to ensure a good fit is achieved.
Incompatibilities: Not applicable.
Storage
Store at temperatures not exceeding 30°C. Store the inhaler with the mouthpiece down. Always replace the mouthpiece cover after using Budesonide/Formoterol (SYMBICORT RAPIHALER).
Shelf-life: The shelf-life after removal from the foil pouch is 3 months.
Shelf-life: The shelf-life after removal from the foil pouch is 3 months.
Action
Pharmacotherapeutic group: Adrenergics and other drugs for obstructive airway diseases. ATC code: R03AK07.
Pharmacology: Pharmacodynamics: Mechanism of action and pharmacodynamic effects: Budesonide/Formoterol (SYMBICORT RAPIHALER) contains budesonide and formoterol, which have different modes of action and show additive effects in terms of reduction of asthma and COPD exacerbations. The specific properties of budesonide and formoterol allow the combination to be used as maintenance treatment of asthma. The respective mechanisms of action of both drugs are discussed as follows.
Budesonide: Budesonide is a glucocorticosteroid which when inhaled has a rapid (within hours) and dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse effects than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.
Formoterol: Formoterol is a selective beta2-adrenergic agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose dependent, with an onset of effect within 1-3 minutes after inhalation. The duration of effect is at least 12 hours after a single dose.
Budesonide Formoterol (SYMBICORT RAPIHALER): Clinical Efficacy in Asthma: Therapeutic equivalence between Budesonide/Formoterol (SYMBICORT RAPIHALER) and Budesonide/Formoterol (SYMBICORT TURBUHALER) was demonstrated in three clinical efficacy and safety studies including asthmatic patients from 6 to 79 years of age and one long-term safety study in adolescents and adults with asthma. The safety profile of Budesonide/Formoterol (SYMBICORT RAPIHALER) has been shown to be as safe and well tolerated as Budesonide/Formoterol (SYMBICORT TURBUHALER). As a result of demonstrating therapeutic equivalence, the clinical efficacy of Budesonide/Formoterol (SYMBICORT RAPIHALER) in asthma described as follows is based on studies conducted with Budesonide/Formoterol (SYMBICORT TURBUHALER).
It has been shown in a separate study that Budesonide/Formoterol (SYMBICORT RAPIHALER) can be used safely with a named spacer device in children.
Budesonide/Formoterol (SYMBICORT TURBUHALER): Clinical Efficacy for Symbicort Maintenance Therapy in Asthma: Clinical studies with Budesonide/Formoterol (SYMBICORT TURBUHALER) have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations. The effect on lung function of Budesonide/Formoterol (SYMBICORT TURBUHALER) given as maintenance dose only was equal to that of budesonide and formoterol administered in separate inhalers in adults and exceeded that of budesonide alone in adults and children. All treatment arms used a short acting β-agonist as needed. There was no sign of attenuation of the anti-asthmatic effect over time.
In a 12-week paediatric study 85 children aged 6-11 years were treated with a maintenance dose of Symbicort (2 inhalations of 80/4.5 micrograms/inhalation twice daily), and a short-acting beta2-agonist as needed. Lung function was improved and the treatment was well tolerated compared to the corresponding dose of budesonide Turbuhaler.
Clinical Efficacy in COPD: Budesonide/Formoterol (SYMBICORT RAPIHALER): In one 12-month study and one 6-month study in patients with COPD, Budesonide/Formoterol (SYMBICORT RAPIHALER) 160/4.5 was superior to placebo, budesonide and formoterol for post-dose FEV1 and predose FEV1. In the 12-month study, Budesonide/Formoterol (SYMBICORT RAPIHALER) was also superior to placebo and formoterol for both the number of, and the time to first severe COPD exacerbation (a worsening of COPD requiring oral steroid use of hospitalization.) Thus, the contribution of both budesonide and formoterol to the effect of Budesonide/Formoterol (SYMBICORT RAPIHALER) was demonstrated. Budesonide/Formoterol (SYMBICORT RAPIHALER) 160/4.5 also significantly reduced breathlessness, daily rescue medication use, night-time awakenings and improved health-related quality of life compared with placebo in both studies. Serial FEV1 measures over 12 hours were obtained in subsets of patients in both studies. The median time to onset of bronchodilation (>15% improvement in FEV1) was seen within 5 minutes at the end of treatment in patients receiving Budesonide/Formoterol (SYMBICORT RAPIHALER) 160/4.5. Maximal improvement in FEV1 occurred at approximately 2 hours post-dose and post-dose bronchodilator effect was generally maintained over 12 hours. The treatment was well tolerated.
Pharmacokinetics: Absorption: Budesonide/Formoterol (SYMBICORT RAPIHALER): There was no evidence of pharmacokinetic interactions between budesonide and formoterol when given together.
In studies where Budesonide/Formoterol (SYMBICORT RAPIHALER) was administered to healthy subjects and patients with moderate asthma, peak plasma concentrations for budesonide occurred approximately 30 minutes and for formoterol 10 minutes after dosing. Peak plasma concentrations were 30-40% higher in healthy subjects compared to asthma patients. However, the total systemic exposure was comparable to that in asthma patients.
In repeat dose studies plasma concentrations of budesonide and formoterol generally increased in proportion to dose.
Collectively, in pharmacokinetic studies conducted in adults with asthma, systemic exposure to budesonide and formoterol administered via Budesonide/Formoterol (SYMBICORT RAPIHALER) was lower than when given via the monoproduct Budesonide (Budecort TURBUHALER). Collectively, the pharmacokinetic data from clinical efficacy and safety studies indicate that Budesonide/Formoterol (SYMBICORT RAPIHALER) delivers a comparable amount of budesonide to the systemic circulation, and thus the lung, as do budesonide pMDI and Budesonide (BUDECORT TURBUHALER). The results of the systemic exposure for formoterol were generally similar when administered via Budesonide/Formoterol (SYMBICORT RAPIHALER).
Budesonide/Formoterol (SYMBICORT TURBUHALER): The systemic bioavailability of budesonide and formoterol was comparable for the two treatments Budesonide/Formoterol (SYMBICORT RAPIHALER) and Budesonide/Formoterol (SYMBICORT TURBUHALER).
Distribution and Biotransformation: Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of distribution is about 4 L/kg for formoterol and 3 L/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O-demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6 beta-hydroxy-budesonide and 16α-hydroxy-prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.
Elimination: The major part of a dose of formoterol is eliminated by metabolism in the liver followed by renal excretion. After inhalation of formoterol via Turbuhaler, 8% to 13% of the delivered dose of formoterol is excreted unmetabolised in the urine. Formoterol has a high systemic clearance (approximately 1.4 L/min) and the terminal elimination half-life averages 17 hours.
Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are excreted in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
Budesonide has a systemic clearance of approximately 0.5 L/min in 4-6 years old asthmatic children. Per kg body weight children have a clearance, which is approximately 50% greater than in adults. The terminal half-life of budesonide after inhalation is approximately 2.3 hours in asthmatic children. The pharmacokinetics of formoterol in children has not been studied.
The pharmacokinetics of budesonide or formoterol in elderly and in patients with renal failure is unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.
Toxicology: Preclinical safety data: The toxicity observed in animal studies with budesonide and formoterol was similar whether budesonide or formoterol were given in combination or separately. The effects were associated with pharmacological actions and dose dependent.
In animal reproduction studies, glucocorticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses (see Use in Pregnancy & Lactation). Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses, as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant to man.
Budesonide/Formoterol (SYMBICORT RAPIHALER) contains the excipients povidone (polyvinylpyrrolidone) K25, macrogol (polyethylene glycol) 1000 and the pressurised liquid propellant apaflurane (HFA 227). The safe use of apaflurane has been fully evaluated in preclinical studies. Povidones have a history of safe use in man for many years, which supports the view that povidones are essentially biologically inert. Macrogols are recognized as safe excipients in pharmaceuticals, food and cosmetic products. Furthermore, toxicity studies carried out using Budesonide/Formoterol (SYMBICORT RAPIHALER) have shown no evidence of any local or systemic toxicity or irritation attributable to the excipients.
Pharmacology: Pharmacodynamics: Mechanism of action and pharmacodynamic effects: Budesonide/Formoterol (SYMBICORT RAPIHALER) contains budesonide and formoterol, which have different modes of action and show additive effects in terms of reduction of asthma and COPD exacerbations. The specific properties of budesonide and formoterol allow the combination to be used as maintenance treatment of asthma. The respective mechanisms of action of both drugs are discussed as follows.
Budesonide: Budesonide is a glucocorticosteroid which when inhaled has a rapid (within hours) and dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse effects than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.
Formoterol: Formoterol is a selective beta2-adrenergic agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose dependent, with an onset of effect within 1-3 minutes after inhalation. The duration of effect is at least 12 hours after a single dose.
Budesonide Formoterol (SYMBICORT RAPIHALER): Clinical Efficacy in Asthma: Therapeutic equivalence between Budesonide/Formoterol (SYMBICORT RAPIHALER) and Budesonide/Formoterol (SYMBICORT TURBUHALER) was demonstrated in three clinical efficacy and safety studies including asthmatic patients from 6 to 79 years of age and one long-term safety study in adolescents and adults with asthma. The safety profile of Budesonide/Formoterol (SYMBICORT RAPIHALER) has been shown to be as safe and well tolerated as Budesonide/Formoterol (SYMBICORT TURBUHALER). As a result of demonstrating therapeutic equivalence, the clinical efficacy of Budesonide/Formoterol (SYMBICORT RAPIHALER) in asthma described as follows is based on studies conducted with Budesonide/Formoterol (SYMBICORT TURBUHALER).
It has been shown in a separate study that Budesonide/Formoterol (SYMBICORT RAPIHALER) can be used safely with a named spacer device in children.
Budesonide/Formoterol (SYMBICORT TURBUHALER): Clinical Efficacy for Symbicort Maintenance Therapy in Asthma: Clinical studies with Budesonide/Formoterol (SYMBICORT TURBUHALER) have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations. The effect on lung function of Budesonide/Formoterol (SYMBICORT TURBUHALER) given as maintenance dose only was equal to that of budesonide and formoterol administered in separate inhalers in adults and exceeded that of budesonide alone in adults and children. All treatment arms used a short acting β-agonist as needed. There was no sign of attenuation of the anti-asthmatic effect over time.
In a 12-week paediatric study 85 children aged 6-11 years were treated with a maintenance dose of Symbicort (2 inhalations of 80/4.5 micrograms/inhalation twice daily), and a short-acting beta2-agonist as needed. Lung function was improved and the treatment was well tolerated compared to the corresponding dose of budesonide Turbuhaler.
Clinical Efficacy in COPD: Budesonide/Formoterol (SYMBICORT RAPIHALER): In one 12-month study and one 6-month study in patients with COPD, Budesonide/Formoterol (SYMBICORT RAPIHALER) 160/4.5 was superior to placebo, budesonide and formoterol for post-dose FEV1 and predose FEV1. In the 12-month study, Budesonide/Formoterol (SYMBICORT RAPIHALER) was also superior to placebo and formoterol for both the number of, and the time to first severe COPD exacerbation (a worsening of COPD requiring oral steroid use of hospitalization.) Thus, the contribution of both budesonide and formoterol to the effect of Budesonide/Formoterol (SYMBICORT RAPIHALER) was demonstrated. Budesonide/Formoterol (SYMBICORT RAPIHALER) 160/4.5 also significantly reduced breathlessness, daily rescue medication use, night-time awakenings and improved health-related quality of life compared with placebo in both studies. Serial FEV1 measures over 12 hours were obtained in subsets of patients in both studies. The median time to onset of bronchodilation (>15% improvement in FEV1) was seen within 5 minutes at the end of treatment in patients receiving Budesonide/Formoterol (SYMBICORT RAPIHALER) 160/4.5. Maximal improvement in FEV1 occurred at approximately 2 hours post-dose and post-dose bronchodilator effect was generally maintained over 12 hours. The treatment was well tolerated.
Pharmacokinetics: Absorption: Budesonide/Formoterol (SYMBICORT RAPIHALER): There was no evidence of pharmacokinetic interactions between budesonide and formoterol when given together.
In studies where Budesonide/Formoterol (SYMBICORT RAPIHALER) was administered to healthy subjects and patients with moderate asthma, peak plasma concentrations for budesonide occurred approximately 30 minutes and for formoterol 10 minutes after dosing. Peak plasma concentrations were 30-40% higher in healthy subjects compared to asthma patients. However, the total systemic exposure was comparable to that in asthma patients.
In repeat dose studies plasma concentrations of budesonide and formoterol generally increased in proportion to dose.
Collectively, in pharmacokinetic studies conducted in adults with asthma, systemic exposure to budesonide and formoterol administered via Budesonide/Formoterol (SYMBICORT RAPIHALER) was lower than when given via the monoproduct Budesonide (Budecort TURBUHALER). Collectively, the pharmacokinetic data from clinical efficacy and safety studies indicate that Budesonide/Formoterol (SYMBICORT RAPIHALER) delivers a comparable amount of budesonide to the systemic circulation, and thus the lung, as do budesonide pMDI and Budesonide (BUDECORT TURBUHALER). The results of the systemic exposure for formoterol were generally similar when administered via Budesonide/Formoterol (SYMBICORT RAPIHALER).
Budesonide/Formoterol (SYMBICORT TURBUHALER): The systemic bioavailability of budesonide and formoterol was comparable for the two treatments Budesonide/Formoterol (SYMBICORT RAPIHALER) and Budesonide/Formoterol (SYMBICORT TURBUHALER).
Distribution and Biotransformation: Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of distribution is about 4 L/kg for formoterol and 3 L/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O-demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6 beta-hydroxy-budesonide and 16α-hydroxy-prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.
Elimination: The major part of a dose of formoterol is eliminated by metabolism in the liver followed by renal excretion. After inhalation of formoterol via Turbuhaler, 8% to 13% of the delivered dose of formoterol is excreted unmetabolised in the urine. Formoterol has a high systemic clearance (approximately 1.4 L/min) and the terminal elimination half-life averages 17 hours.
Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are excreted in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
Budesonide has a systemic clearance of approximately 0.5 L/min in 4-6 years old asthmatic children. Per kg body weight children have a clearance, which is approximately 50% greater than in adults. The terminal half-life of budesonide after inhalation is approximately 2.3 hours in asthmatic children. The pharmacokinetics of formoterol in children has not been studied.
The pharmacokinetics of budesonide or formoterol in elderly and in patients with renal failure is unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.
Toxicology: Preclinical safety data: The toxicity observed in animal studies with budesonide and formoterol was similar whether budesonide or formoterol were given in combination or separately. The effects were associated with pharmacological actions and dose dependent.
In animal reproduction studies, glucocorticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses (see Use in Pregnancy & Lactation). Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses, as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant to man.
Budesonide/Formoterol (SYMBICORT RAPIHALER) contains the excipients povidone (polyvinylpyrrolidone) K25, macrogol (polyethylene glycol) 1000 and the pressurised liquid propellant apaflurane (HFA 227). The safe use of apaflurane has been fully evaluated in preclinical studies. Povidones have a history of safe use in man for many years, which supports the view that povidones are essentially biologically inert. Macrogols are recognized as safe excipients in pharmaceuticals, food and cosmetic products. Furthermore, toxicity studies carried out using Budesonide/Formoterol (SYMBICORT RAPIHALER) have shown no evidence of any local or systemic toxicity or irritation attributable to the excipients.
MedsGo Class
Antiasthmatic & COPD Preparations
Features
Brand
Symbicort Rapihaler
Full Details
Dosage Strength
80mcg / 4.5mcg per Actuation
Drug Ingredients
- Budesonide
- Formoterol
Drug Packaging
Inhalation Aerosol 120 doses
Generic Name
Budesonide / Formoterol Fumarate Dihydrate
Dosage Form
Inhalation Aerosol
Registration Number
DR-XY45700
Drug Classification
Prescription Drug (RX)
View all variations as list
| CODE | Dosage Strength | Drug Packaging | Availability | Price | ||
|---|---|---|---|---|---|---|
|
RXDRUG-DR-XY45701
|
In stock
|
₱91500 | |||
|
RXDRUG-DR-XY45700
|
In stock
|
₱74900 |
Please sign in so that we can notify you about a reply